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Abstract 
Rationale: A significant population of patients with severe asthma and chronic obstructive 
pulmonary disease is less responsive to β2-adrenoceptor agonists and corticosteroids, and there are 
possible safety issues concerning long-term use of these drugs. Inhaled prostaglandin E2 (PGE2) is 
antiinflammatory and a bronchodilator in patients with asthma, but it also causes cough. 
Objectives: We aimed to identify the receptor involved in PGE2-induced sensory nerve activation and 
cough using a range of in vitro and in vivo techniques. 
Methods: Depolarization of vagal sensory nerves (human, mouse, and guinea pig) was assessed as an 
indicator of sensory nerve acitivity. Cough was measured in a conscious guinea pig model. 
Measurements and Main Results: Using an extensive range of pharmacological tools, we identified 
that the EP3 receptor mediates PGE2-induced depolarization of sensory nerves in human, mouse, 
and guinea pig. Further supporting evidence comes from data showing that responses to PGE2 are 
virtually abolished in isolated vagus nerves from EP3-deficient mice (Ptger3−/−). Finally, we 
demonstrated the role of the EP3 receptor in vivo using a selective EP3 antagonist to attenuate 
PGE2-induced cough. 
Conclusions: Identification of the receptor mediating PGE2-induced cough represents a key step in 
developing a drug that is antiinflammatory and a bronchodilator but without unwanted side effects. 
 
Asthma and chronic obstructive pulmonary disease (COPD) represent major problems for world 
public health as chronic respiratory diseases are currently the fourth leading cause of death (1). 
Asthma is characterized by reversible airflow obstruction caused by bronchoconstriction, 
inflammation, and airway hyperresponsiveness. In contrast, the airflow obstruction in COPD is not 
fully reversible and often worsens progressively (2). Currently, bronchodilators, such as long-acting 
β2-adrenergic receptor agonists, are the mainstay treatment but often fail to relieve symptoms of 
COPD and severe asthma (3) and some possible concerns have been raised over long-term use (4). 
Inhaled corticosteroids successfully control airway inflammation in most patients with asthma; 
however, they are of negligible benefit in patients with severe asthma (5) and are often not effective 
in patients with COPD (6). Concerns exist over long-term side effects of high doses of inhaled 
corticosteroids (7). Collectively these factors represent a significant need for the development of 
new, safe therapies for airway inflammatory diseases. 
Inhaled prostaglandin E2 (PGE2) is a bronchodilator in normal subjects (8–10) and in patients with 
asthma and chronic bronchitis (8, 11). In addition, PGE2 has antiinflammatory properties in patients 
with asthma (12, 13), providing an ideal dual therapy for the treatment of these diseases. Despite 
the benefits of inhaled PGE2, the development of prostanoid agonists for the treatment of airway 
inflammatory diseases has been hindered as prostanoids induce irritancy of the upper airway 
resulting in a reflex cough. Cough is initiated by stimulation of sensory afferent nerve endings in the 
airways. PGE2 excites airway afferent nerves (14, 15), which concurs with the transient cough seen 
in both normal subjects and patients with asthma during studies with inhaled PGE2 (8, 10, 13). 
However, it is not yet known how PGE2 causes this tussive response. 
There are currently nine known prostanoid receptors. PGE2 has relatively low affinity for the FP, IP, 
TP, DP, and CRTh2 receptors (encoded by Ptgfr, Ptgir, Tbxa2r, Ptgdr, and Gpr44 genes) and acts 
predominantly via the EP receptors. The EP receptors have been subclassified into EP1, EP2, EP3, 
and EP4 (encoded by Ptger1–Ptger4 genes) (16–18) and distinct signaling pathways initiate diverse 
and opposing downstream effects in different tissues (17–19). 
To date, no study has investigated the receptor responsible for the PGE2-induced cough. The results 
of this study could provide key proof of concept data demonstrating the selectivity profile required 
for any candidate compound to elicit antiinflammatory/bronchodilator effects without the sensory 
irritant side effect liability. To identify the tussive receptor, we used models of sensory nerve 
activation and cough. Guinea pigs, as the only rodents that possess a cough reflex, are the most 
appropriate species for investigating cough in vivo. Although mice do not cough per se, comparing 
sensory nerve activation in nerves from prostanoid receptor–deficient mice is fundamental to this 
study. Thus, we established that responses to PGE2 in guinea pig and mouse mimic those in human 
vagal sensory nerves. Using a pharmacological approach and prostanoid receptor–deficient mice, we 
provide substantial evidence that the EP3 receptor mediates PGE2-induced sensory nerve activation. 
Finally we provide in vivo proof of concept data demonstrating inhibition of PGE2-induced cough by 
a selective EP3 receptor antagonist. 
METHODS 
Animals 
Male C57BL/6 mice (18–20 g) and Male Dunkin-Hartley guinea pigs (250–350 g) were purchased 
from Harlan (Bicester, Oxon, UK). Breeding pairs of mice devoid of one of the following genes: Ptger1 
(EP1), Ptger2 (EP2), Ptger3 (EP3), Ptgdr (DP), Ptgfr (FP), Ptgir (IP), or Tbxa2r (TP), had been 
backcrossed at least eight times onto the C57BL/6 background. Ptger4−/− mice do not survive on the 
C57BL/6 background due to patent ductus arteriosus (20), so they were backcrossed on a mixed 
background of 129/Ola X C57BL/6. Mice were kindly provided by Dr. Shuh Narumiya, Kyoto 
University, and breeding colonies maintained at Imperial College, London. Experiments were 
performed in accordance with the UK Home Office guidelines for animal welfare based on the 
Animals (Scientific Procedures) Act 1986. 
Characterizing Responses to PGE2 in Isolated Vagus Nerves 
Sensory nerve depolarization was measured as previously described (21–23). Concentrations of 
vehicle (0.1% ethanol) or PGE2 were applied to guinea pig, mouse, or human nerves in a random 
order for 2 minutes each, washing the tissue in between. No more than five stimulations were 
generated per section of nerve. Human vagus nerves were obtained from donor patients for heart or 
heart/lung transplants performed at The Royal Brompton or Harefield Hospital. Approval was 
obtained from the Royal Brompton and Harefield ethics committee after receiving the relevant 
consents from relatives. 
Investigating PGE2 Inhibition Using Selective Antagonists 
A concentration of 10 μM PGE2 was selected from the concentration response and the effect of a 
range of antagonists was investigated in the guinea pig and mouse: 0.1% dimethyl sulfoxide (DMSO) 
vehicle, 1 μM GW848687X (EP1) (24), 0.2 μM L826266 (EP3) (25), 1 μM GW627368X (EP4) (26), 10 
μM AL8810 (FP) (27), 10 μM AH6809 (EP1/2DP) (28), 1 μM SQ29548 (TP) (29), and 1 μM RO3244794 
(IP) (30). Concentrations of antagonists were selected that were approximately 100-fold the pA2 
value (defined as the negative logarithm of the molar concentration of an antagonist that would 
produce a twofold shift in the concentration–response curve for an agonist) as is common practice. 
Where available, agonists that act preferentially on one of the receptors (10 μM) were profiled in 
parallel to PGE2:PGF2α (FP), PGD2 (DP), iloprost (IP), and U46619 (TP). Agonists were applied to the 
nerve for 2 minutes and washed. A second response was elicited to ensure the response was 
reproducible. The antagonist was then perfused onto the nerve for 10 minutes and immediately 
after, PGE2 (or agonist) in the presence of antagonist was applied and the inhibition recorded. The 
nerve was then washed and agonist response repeated to ensure the nerve was still viable. Any 
antagonists that inhibited the PGE2-induced depolarization were then investigated in the human 
vagus nerve. 
Investigating the Effect of an EP3 Antagonist on PGE2-induced Cough In Vivo 
The procedure for measuring coughs in conscious guinea pigs has previously been described (22, 23, 
31). Male Dunkin-Hartley guinea pigs (250–350 g, Charles River, L'Arbresle, France) were exposed to 
a 10-minute aerosol of PGE2 (30, 100, or 300 μg/ml) and the number of coughs recorded. Once the 
optimal concentration of PGE2 had been established, a separate group of animals were dosed with 
vehicle (0.5% methylcellulose + 0.2% Tween 80 in saline, intraperitoneally) or the EP3 antagonist 
L826266 (300 mg/kg, interperitoneally) 40 minutes before challenge with PGE2. This high dose was 
chosen because the pharmacokinetic profile demonstrated low plasma levels and a high degree of 
plasma protein binding after intraperitoneal dosing (report from Merck Frosst, Montreal, PQ, 
Canada). It was therefore predicted that this dose would be required to have some impact on the 
PGE2 response. Indeed the data from a guinea pig pharmacokinetic study and assessment of the 
impact of plasma binding on antagonist potency suggested that even at this high dose there would 
only be approximately 0.1 μM of unbound (i.e., active) antagonist. Unfortunately, there was 
insufficient compound available to dose at a higher level and no other appropriate tool compounds 
available. Coughs were counted as described above. 
Compounds and Materials 
The EP1 antagonist GW848687X (24) and the EP4 antagonist GW627368X (26) were kind gifts from 
GlaxoSmithKline, and the EP3 antagonist L826266 (25) and IP antagonist RO3244794 (30) were kind 
gifts from Merck Frosst and Roche Palo Alto (Palo Alto, CA), respectively. The FP antagonist AL8810 
(27), EP1/2DP antagonist AH6809 (28), and TP antagonist SQ29548 (29) were purchased from 
Cayman Europe. All antagonists were made in DMSO and stocks stored (1 mM or 10 mM) until 
required. PGE2, PGF2α, and PGD2 were purchased from Sigma Aldrich (Poole, UK) and dissolved in 
ethanol to 10 mM. U46619 and Iloprost were purchased from Cayman Europe (Tallinn, Estonia) and 
dissolved in DMSO to 10 mM. Capsaicin was purchased from Sigma and stored in DMSO at 1 mM 
until required. A low pH solution was made to pH 5 as previously described (32). Krebs compounds 
were obtained from BDH (Dorset, UK) and all other chemicals and reagents were from Sigma Aldrich. 
Data Analysis and Statistics 
Antagonism of prostanoid agonists was analyzed using a two-tailed paired t test, comparing 
responses to agonist (in the same piece of vagus nerve) in the absence and presence of antagonist. 
Responses to PGE2 in prostanoid receptor–deficient mice were analyzed using Kruskal-Wallis test for 
multiple comparisons with Dunns post hoc test, comparing the responses in each prostanoid 
receptor–deficient group to the wild-type control. Inhibition of the PGE2-induced cough was 
analyzed using Mann Whitney U test for nonparametric data. Data are presented as mean ± SEM 
and statistical significance was denoted as P less than 0.05. 
RESULTS 
PGE2 Activates Isolated Vagus Nerves 
Our model of sensory nerve activation has previously been characterized and is predictive of agents 
that cause cough in vivo (21, 22). Responses to PGE2 in the guinea pig vagus nerve emulate 
responses in the human vagus nerve (23). In the present study we established a concentration-
dependent increase in depolarization to PGE2 (Figure 1) in mouse, guinea pig, and human isolated 
vagus nerves. With no disparity between the species in the response to PGE2, we deduce that 
responses in guinea pig and mice are representative of those in human nerves. 
Figure 1. 
 
Depolarization (mV) of mouse, guinea pig, and human vagus nerves by vehicle (0.1% ethanol) or 
concentrations of PGE2 (μM). Data are expressed as mean ± SEM of four to six experiments in 
guinea pig and mouse and two to four experiments in human isolated vagus nerves.Selective EP3 
Receptor Antagonist Inhibits PGE2-induced Activation of Sensory Nerves 
 After confirming PGE2-induced depolarization in all three species, we investigated the receptor 
responsible in guinea pig isolated nerves using an array of prostanoid receptor agonists and 
antagonists. Antagonists at FP (AL8810), EP1/2DP (AH6809), TP (SQ29548), and IP (RO3244794) 
inhibited their corresponding receptor agonists (PGF2α, PGD2, U46619, and Iloprost, respectively) 
but did not influence PGE2-induced depolarization (Figure 2A). Vehicle or antagonists at EP1 
(GW848687X) and EP4 (GW627368X) had no effect on PGE2; however, the EP3 antagonist (L826266 
[0.2 μM]) attenuated depolarization to PGE2 in the guinea pig vagus nerve (Figure 2B). Example 
traces of the effect of the FP antagonist AL8810 on PGF2α (Figure 2C) and PGE2 (Figure 2D) are 
presented; AL8810 inhibited the responses to PGF2α but did not attenuate PGE2. After the 
antagonist was washed out, the agonist responses were recovered after all antagonists. The same 
range of antagonists was investigated in wild-type mice and the effects were mirrored in both 
species. The EP3 antagonist significantly inhibited PGE2-induced (10 μM) depolarization of the 
mouse vagus nerve by 64.8 ± 2.8% (n = 4; P < 0.05), whereas no inhibition by the other antagonists 
was observed (data not shown). 
Figure 2. 
 
Percentage inhibition of agonist-induced depolarization by selective prostanoid receptor 
antagonists in guinea pig vagus nerves. (A) The inhibition of PGE2 (solid bars) or selective agonists 
(open bars; 10 μM PGF2α [FP], PGD2 [DP], U46619 [TP], and Iloprost [IP]) by antagonists 10 μM 
AL8810 (FP), 10 μM AH6809 (EP1/2DP), 1 μM SQ29548 (TP), and 1 μM RO3244794 (IP). (B) 
Inhibition of PGE2-induced depolarization (10 μM) by vehicle (0.1% dimethyl sulfoxide) and 
antagonists at EP1 (1 μM GW848687X), EP3 (0.2 μM L826266), and EP4 (1 μM GW627368X). (A, B) 
data represent mean ± SEM, n = 4, * P < 0.05 comparing response in the same nerve before and 
after antagonist. Representative traces showing the effects of the FP antagonist AL8810 on (C) 
PGF2α and (D) PGE2. 
 
Further investigation of the EP3 antagonist illustrated that L826266 concentration-dependently 
inhibited PGE2 (Figure 3A). L826266 also completely abolished depolarization induced by 
sulprostone, an agonist at the EP3 receptor, confirming that L826266 is indeed acting as an EP3 
antagonist in this system (Figure 3B). Furthermore, L826266 did not attenuate depolarization 
induced by 1 μM capsaicin or low pH solution (which both induce a tussive response in vivo) (Figure 
3B) illustrating that the antagonist is inhibiting depolarization specifically induced by PGE2. The EP3 
antagonist (at a submaximal concentration of 0.2 μM) had a remarkably similar effect in the human 
vagus nerve, inhibiting PGE2 by 80% (Figure 3C), suggesting that the receptor responsible for PGE2-
induced sensory nerve activation is the same in guinea pigs, mice, and humans. 
Figure 3. 
 
Characterization of the EP3 antagonist L826266. (A) Percentage inhibition of 10 μM PGE2 by 
L826266 (0.1% dimethyl sulfoxide, 0.02, 0.2, 2, and 20 μM; n = 4). (B) Percentage inhibition of 
sulprostone (10 μM), capsaicin (1 μM), and low pH (pH 5) by L826266 (2 μM, n = 4) in guinea pig 
vagus nerves. (A, B) Data are expressed as mean ± SEM, * P < 0.05 comparing responses in the 
same nerve before and after antagonist. (C) A copy of an original trace in which a concentration 
of 0.2 μM EP3 antagonist inhibited PGE2-induced depolarization in the human vagus nerve by 
80%. 
 
Presence of the EP3 Receptor Is Essential for PGE2-induced Sensory Nerve Activation 
To confirm the role of the EP3 receptor in PGE2-induced sensory nerve activation, we used isolated 
vagus nerves from prostanoid receptor–deficient mice (Figure 4A). Isolated nerves from wild-type 
mice depolarized to the expected magnitude, whereas Ptger3−/− mice had a significantly smaller, or 
completely abolished, response (Figure 4B). All of the mice were genotyped by a standard PCR 
technique. An example gel of amplification of DNA in the Ptger3 gene in wild-type and Ptger3−/− 
mouse tissue can be seen in Figure 4C. Primers for the wild type produced a band at 350 bp and 
Ptger3−/− at 550 bp. 
Figure 4. 
 
Investigating responses to PGE2 in prostanoid receptor-deficient mice. (A) Responses to 10 μM 
PGE2 in isolated vagus nerves from prostanoid receptor–deleted mice. The Ptger3
−/− mice had a 
significantly decreased response to PGE2 compared with the C57BL/6 wild-type mice (n = 4–6; * P 
< 0.05). Data are expressed as mean ± SEM. (B) Representative trace showing the depolarization 
to 10 μM PGE2 in the wild-type C57BL/6 mice (left) and no effect of PGE2 in the Ptger3−/− mice 
(right). (C) Example gel of genotyping for the Ptger3−/− mice. Primers for the wild-type gene 
produced a band at 350 bp and Ptger3−/− at 550 bp. 
EP3 Receptor Antagonist Attenuates PGE2-induced Cough In Vivo 
The role of the EP3 receptor in PGE2-induced sensory nerve activation and cough was then 
investigated in vivo. Guinea pigs were exposed to an aerosol of 30, 100, or 300 μg/ml PGE2 for 10 
minutes to establish a suitable concentration (n = 8). The number of coughs were recorded: 30 
μg/ml (0 coughs), 100 μg/ml (3.3 ± 3.3 coughs), and 300 μg/ml (12.6 ± 4 coughs). A concentration of 
300 μg/ml was selected for use in subsequent experiments. In the study in which we tested the EP3 
receptor antagonist the numbers of coughs induced was higher (Figure 5). The reason for this is 
unknown but could be due to in vivo variation inherent in working with conscious models and/or the 
additional stress involved in dosing. 
 
 
 
Figure 5. 
 
Inhibition of PGE2-induced cough with L826266. Guinea pigs were dosed (interperitoneally) with 
vehicle (n = 5) or 300 mg/kg L826266 (n = 6) 40 minutes before cough challenge. Data are 
represented as mean ± SEM, * P < 0.05 comparing vehicle to antagonist group. 
Investigation of L826266 on PGE2-induced cough revealed that the antagonist significantly 
decreased the number of coughs in response to aerosolized PGE2. Although one may expect that the 
high dose used would block the cough response completely, analysis of the pharmokinetic profile 
and level of plasma protein binding (performed by Merck Frosst and detailed in Methods) would 
suggest actual unbound/active levels to be around 0.1 μM. Data from the isolated vagus 
experiments (Figure 3) show that at this concentration PGE2 responses are only attenuated by 
approximately 50%, which is remarkably reminiscent of the impact in the cough system. In addition 
we have data (not shown) in isolated guinea pig trachea showing that 2 μM (i.e., 20 times higher 
than predicted levels in the cough study) of this compound does not affect PGE2-induced 
bronchodilation (reported to be through other EP receptors) (33) suggesting that this compound is 
unlikely to be acting on other EP receptors. Together these data confirm that the EP3 receptor 
mediates PGE2-induced cough (Figure 5). 
DISCUSSION 
Current treatments for airway inflammatory disease, such as inhaled glucocorticoids and long-acting 
β-agonists, have been associated with significant side effects (3, 4, 7) and furthermore, these 
treatments are often less effective in certain subpopulations of patients (5, 6). There is therefore an 
unmet need to develop new, safe drugs, free of adverse side effects, for the treatment of asthma 
and COPD. PGE2 has been shown to be a bronchodilator and an antiinflammatory agent in several 
studies in patients with asthma (11–13). However, the development of prostanoid agonists for the 
treatment of airway inflammatory diseases has been hindered due to airway irritancy and cough (8, 
10, 13). Identifying the receptor triggering the reflex cough represents a major step in the 
development of a PGE2 analog that is a bronchodilator and an antiinflammatory agent but devoid of 
tussive side effects. 
To commence our investigation we measured vagal sensory nerve activation, because the vagus 
nerves supply the majority of the sensory nerve fibers to the airway, using the isolated vagus nerve 
preparation. We have previously shown that responses to tussive stimuli in human vagus nerves are 
representative of those from guinea pig nerves (23). Here, we generated data comparing the 
responses to PGE2 in mouse, guinea pig, and human species. Therefore we can conclude from these 
experiments that PGE2 has a remarkably similar effect on human, mouse, and guinea pig vagus 
nerves. This would suggest that guinea pig and mouse vagi are representative of the effects of PGE2 
in human tissue. Moreover, because PGE2 causes both sensory nerve activation and cough in 
humans and guinea pigs, we have evidence that our model of sensory nerve activity is 
representative of the human cough reflex. 
Once we established that PGE2 activates isolated vagal sensory nerves, we proceeded to investigate 
pharmacologically the receptor responsible for PGE2-induced depolarization using a range of 
prostanoid antagonists. The EP3 antagonist L826266 was the only antagonist investigated that 
attenuated responses to PGE2 in both guinea pig and mouse. Furthermore, we have provided 
evidence that this antagonism is mirrored in the isolated human nerve, illustrating that the EP3-
mediated sensory nerve activation, elicited by PGE2, is an effect that is translated across species. 
Capsaicin and a low pH solution were not inhibited by the EP3 antagonist, suggesting that the 
antagonist is specifically inhibiting PGE2-induced sensory nerve activation rather than acting as a 
general inhibitor of nerve depolarization. 
Although significant pharmacological evidence that the EP3 receptor is responsible for PGE2-induced 
sensory nerve activity was generated, we then corroborated these data by using isolated nerves 
from mice devoid of one of the prostanoid receptors. The Ptger3−/− mice, lacking EP3 receptors, had 
a diminished response to PGE2, whereas responses in nerves from other prostanoid receptor–
deficient mice (Ptger1−/−, Ptger2−/−, Ptger4−/−, Ptgfr−/−, Ptgdr−/−, Ptgir−/−, Tbxa2r−/−) depolarized 
to the same magnitude as wild types. This research culminated in the demonstration that L826266 
inhibited PGE2-induced cough in our in vivo guinea pig model. Taken together these studies confirm 
that cough induced by PGE2 is caused mainly, if not solely, by activation of the EP3 receptor. 
PGE2 is commonly presumed to be proinflammatory and has been implicated in several 
inflammatory disease conditions, including rheumatoid arthritis (34) and UVB-induced cutaneous 
inflammation (35). However, in humans, the lung appears to be unique in that PGE2 has beneficial 
effects (8, 9, 11–13) as well as unwanted effects (8, 13). The receptor(s) responsible for the 
beneficial effects seem to differ from the EP3 receptor causing the detrimental cough. Using human 
airway smooth muscle and rodent models, there is evidence that the EP2 receptor is responsible for 
the PGE2-induced bronchodilation (36–38). Antiinflammatory effects of PGE2 have been identified in 
both human (12, 13) and rodent models (39). One isolated study has suggested that, in a mouse 
model, activation of the EP3 receptor could suppress ovalbumin-induced inflammation (40). 
However, the wealth of information available, especially from human cell–based assays, would 
suggest that the receptor(s) responsible for the antiinflammatory actions of PGE2 are the EP2 and/or 
the EP4 receptor subtype (41–45). 
Rationale for the development of a PGE2 analog that does not activate the EP3 receptor is not just 
limited to cough, as the EP3 receptor mediates other detrimental effects of PGE2 in the airways. 
Although PGE2-mediated bronchodilation is believed to be via the EP2 receptor, bronchoconstrictor 
effects of PGE2 have been shown to act through EP1 and EP3 (33). What is more, the EP3 receptor 
has been implicated in the chemotaxis of mast cells to sites of inflammation (46). 
In summary, we have established in this current study that PGE2-induced sensory nerve activation 
and cough are mediated via the EP3 receptor. Our research, and other published data, suggests that 
the unwanted effects of PGE2 (proinflammatory effects, bronchoconstriction, and cough) are 
mediated by the EP3 receptor and beneficial effects are likely to act via a different receptor. This 
research provides considerable support for the development of a PGE2 analog that does not activate 
the EP3 receptor, thereby providing a novel therapy for airway inflammatory diseases that is 
antiinflammatory and a bronchodilator but devoid of tussive side effects. 
Acknowledgments 
The authors thank the following for their intellectual contribution and kind gifts: D. Slipetz, M. 
Gallant, R. Forget (Merck Frosst) for L826266; R. McArthur-Wilson (GlaxoSmithKline) for GW848687X 
and GW627368X; Roche Palo Alto for RO3244794; S. Narumiya (Kyoto University) and T. Maruyama 
(ONO Pharmaceuticals) for the prostanoid receptor-deficient mice. The authors also thank M. Catley, 
D. Clarke, M. Collins, E. Hardaker, D. Hele, J. Nasra, and S. Wong for their help and advice with the 
experiments. They also thank M. Johnson and T. Nials (GlaxoSmithKline) for their support and 
encouragement. 
Notes 
 
Supported by GlaxoSmithKline (S.A.M., M.A.B.), and a project grant from the Medical Research 
Council (MRC), UK (G0800196) (M.A.B.). The research was also funded by a project grant from the 
MRC, UK (G0800195). The human tissue work was funded by an Experimental Medicine Grant 
(G0502019) from the MRC, UK. The human tissue experiments in this study were undertaken with 
the support of the NIHR Biomedical Research Unit in Advanced Lung Disease at the Royal Brompton 
and Harefield NHS Foundation Trust and Imperial College London and partly funded by the NIHR 
Biomedical Research Unit funding scheme. 
Originally Published in Press as DOI: 10.1164/rccm.200903-0388OC on September 3, 2009 
Conflict of Interest Statement: S.A.M. does not have a financial relationship with a commercial entity 
that has an interest in the subject of this manuscript. M.A.B. does not have a financial relationship 
with a commercial entity that has an interest in the subject of this manuscript. M.G.B. received 
$5,001–$10,000 from GlaxoSmithKline, $5,001–$10,000 from Sound Pharma, and $5,001–$10,000 
from AstraZeneca in consultancy fees; $1,001 to $5,000 from Vectura, $1,001–$5,000 from 
GlaxoSmithKline, and $1,001–$5,000 from Schering Plough in advisory board fees; and $10,001– 
$50,000 from AstraZeneca and $10,001–$50,000 from Novartis in industry-sponsored grants. 
  
References 
1. Minino AM, Heron MP, Murphy SL, Kochanek KD. Deaths: final data for 2004. Natl Vital Stat Rep 
2007;55:1–119.  
2. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin 
R, van Weel C, et al. Global strategy for the diagnosis, management, and prevention of chronic 
obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532–
555.  
3. Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir 
J 2005;25:1084–1106.  
4. Currie GP, Lee DK, Lipworth BJ. Long-acting beta2-agonists in asthma: not so SMART? Drug Saf 
2006;29:647–656.  
5. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 2005;172:149–160.  
6. Barnes PJ. Inhaled corticosteroids are not helpful in chronic obstructive pulmonary disease. Am J 
Respir Crit Care Med 2000;161:342–344.  
7. Barnes PJ. New therapies for asthma. Trends Mol Med 2006;12:515–520.  
8. Kawakami Y, Uchiyama K, Irie T, Murao M. Evaluation of aerosols of prostaglandins E1 and E2 as 
bronchodilators. Eur J Clin Pharmacol 1973;6:127–132.  
9. Walters EH, Bevan C, Parrish RW, Davies BH, Smith AP. Time-dependent effect of prostaglandin E2 
inhalation on airway responses to bronchoconstrictor agents in normal subjects. Thorax 
1982;37:438–442.   
10. Costello JF, Dunlop LS, Gardiner PJ. Characteristics of prostaglandin induced cough in man. Br J 
Clin Pharmacol 1985;20:355–359.   
11. Melillo E, Woolley KL, Manning PJ, Watson RM, O'Byrne PM. Effect of inhaled PGE2 on exercise-
induced bronchoconstriction in asthmatic subjects. Am J Respir Crit Care Med 1994;149:1138–1141.  
12. Pavord ID, Wong CS, Williams J, Tattersfield AE. Effect of inhaled prostaglandin E2 on allergen-
induced asthma. Am Rev Respir Dis 1993;148:87–90.  
13. Gauvreau GM, Watson RM, O'Byrne PM. Protective effects of inhaled PGE2 on allergen-induced 
airway responses and airway inflammation. Am J Respir Crit Care Med 1999;159:31–36.  
14. Coleridge HM, Coleridge JC, Ginzel KH, Baker DG, Banzett RB, Morrison MA. Stimulation of 
‘irritant’ receptors and afferent C-fibres in the lungs by prostaglandins. Nature 1976;264:451–453.  
15. Mohammed SP, Higenbottam TW, Adcock JJ. Effects of aerosol-applied capsaicin, histamine and 
prostaglandin E2 on airway sensory receptors of anaesthetized cats. J Physiol 1993;469:51–66.   
16. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of 
prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. 
Pharmacol Rev 1994;46:205–229.  
17. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties and functions. 
Phys Rev 1999;79:1193–1226.  
18. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. 
Annu Rev Pharmacol Toxicol 2001;41:661–690.  
19. Tsuboi K, Sugimoto Y, Ichikawa A. Prostanoid receptor subtypes. Prosaglandins Other Lipid 
Mediat 2002;68–69:535–556.  
20. Segi E, Sugimoto Y, Yamasaki A, Aze Y, Oida H, Nishimura T, Murata T, Matsuoka T, Ushikubi F, 
Hirose M, et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient 
mice. Biochem Biophys Res Commun 1998;246:7–12.  
21. Birrell MA, Crispino N, Hele DJ, Patel HJ, Yacoub MH, Barnes PJ, Belvisi MG. Effect of dopamine 
receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma 
and COPD. Br J Pharmacol 2002;136:620–628.   
22. Patel HJ, Birrell MA, Crispino N, Hele DJ, Venkatesen P, Barnes PJ, Yacoub MH, Belvisi MG. 
Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by 
cannabinoid (CB2) receptor activation. Br J Pharmacol 2003;140:261–268.   
23. Belvisi MG, Patel HJ, Freund-Michel V, Hele DJ, Crispino N, Birrell MA. Inhibitory activity of the 
novel CB2 receptor agonist, GW833972A, on guinea-pig and human sensory nerve function in the 
airways. Br J Pharmacol 2008;155:547–557.   
24. Giblin GMP, Bit RA, Brown SH, Chaignot HM, Chowdhury A, Chessell IP, Clayton NM, Coleman T, 
Hall A, Hammond B, et al. The discovery of 6-[2-(5-chloro-2-{[(2,4-
difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a 
potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain. 
Bioorg Med Chem Lett 2007;17:385–389.  
25. Gallant M, Carriere MC, Chateauneuf A, Denis D, Gareau Y, Godbout C, Greig G, Juteau H, 
Lachance N, Lacombe P, et al. Structure-activity relationship of biaryl acylsulfonamide analogues on 
the human EP3 prostanoid receptor. Bioorg Med Chem Lett 2002;12:2583–2586.  
26. Wilson RJ, Giblin GMP, Roomans S, Rhodes SA, Cartwright KA, Shield VJ, Brown J, Wise A, 
Chowshury J, Pritchard S, et al. GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-
benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective 
prostanoid EP4 receptor antagonist. Br J Pharmacol 2003;148:326–339.   
27. Griffin BW, Klimko P, Crider JY, Sharif NA. AL-8810: a novel prostaglandin F2α analog with 
selective antagonist effects at the prostaglandin F2α (FP) receptor. J Pharmacol Exp Ther 
1999;290:1278–1284.  
28. Keery RJ, Lumley P. AH6809, a prostaglandin DP-receptor blocking drug on human platelets. Br J 
Pharmacol 1988;94:745–754.   
29. Ogletree ML, Harris DN, Greenberg R, Haslanger MF, Nakane M. Pharmacological actions of SQ 
29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther 1985;234:435–441.  
30. Bley KR, Bhattacharya A, Daniels DV, Gever J, Jahangir A, O'Yang C, Smith S, Srinivasan D, Ford 
APDW, Jett MF. RO1138452 and RO3244794: characterization of structurally distinct, potent and 
selective IP (prostacyclin) receptor antagonists. Br J Pharmacol 2005;147:335–345.   
31. Lalloo UG, Fox AJ, Belvisi MG, Chung KF, Barnes PJ. Capsazepine inhibits cough induced by 
capsaicin and citric acid but not by hypertonic saline in guinea pigs. J Appl Physiol 1995;79:1082–
1087.  
32. Fox AJ, Urban L, Barnes PJ, Dray A. Effects of capsazepine against capsaicin- and proton-evoked 
excitation of single airway C-fibers and vagus nerve from the guinea-pig. Neuroscience 1995;67:741–
752.  
33. Tilley SL, Hartney JM, Erikson CJ, Jania C, Nguyen M, Stock J, McNeisch J, Valancius C, Panettieri 
RA Jr, Penn RB, et al. Receptors and pathways mediating the effects of prostaglandin E2 on airway 
tone. Am J Physiol Lung Cell Mol Physiol 2003;284:L599–L606.  
34. McCoy JM, Wicks JR, Audoly LP. The role of prostaglandin E2 receptors in the pathogenesis of 
rheumatoid arthritis. J Clin Invest 2002;110:651–658.   
35. Wilgus TA, Parrett ML, Ross MS, Tober KL, Robertson FM, Oberyszyn TM. Inhibition of ultraviolet 
light B-induced cutaneous inflammation by a specific cyclooxygenase-2 inhibitor. Adv Exp Med Biol 
2002;507:85–92.  
36. Norel X, Walch L, Labat C, Gascard JP, Dulmet E, Brink C. Prostanoid receptors involved in the 
relaxation of human bronchial preparations. Br J Pharmacol 1999;126:867–872.   
37. Fortner CN, Breyer RM, Paul RJ. EP2 receptors mediate airway relaxation to substance P, ATP, 
and PGE2. Am J Physiol Lung Cell Mol Physiol 2001;281:L469–L474.  
38. Sheller JR, Mitchell D, Meyrick B, Oates J, Breyer R. EP2 receptor mediates bronchodilation by 
PGE2 in mice. J Appl Physiol 2000;88:2214–2218.  
39. Martin JG, Suzuki M, Maghni K, Pantano R, Ramos-Barbon D, Ihaku D, Nantel F, Denis D, Hamid 
Q, Powell WS. The immunomodulatory actions of prostaglandin E2 on allergic airway responses in 
the rat. J Immunol 2002;169:3963–3969.  
40. Kunikata T, Yamane H, Segi E, Matsuoka T, Sugimoto Y, Tanaka S, Tanaka H, Nagai H, Ichikawa A, 
Narumiya S. Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat 
Immunol 2005;6:524–531.  
41. Clarke DL, Belvisi MG, Catley MC, Yacoub MH, Newton R, Giembycz MA. Identification in human 
airways smooth muscle cells of the prostanoid receptor and signalling pathway through which PGE2 
inhibits the release of GM-CSF. Br J Pharmacol 2004;141:1141–1150.   
42. Ratcliffe MJ, Walding A, Shelton PA, Flaherty A, Dougall IG. Activation of E-prostanoid4 and E-
prostanoid2 receptors inhibits TNF-α release from human alveolar macrophages. Eur Respir J 
2007;29:986–994.  
43. Huang S, Wettlaufer SH, Hogaboam C, Aronoff DM, Peters-Golden M. Prostaglandin E2 inhibits 
collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 
receptor and cAMP signaling. Am J Physiol Lung Cell Mol Physiol 2007;292:L405–L413.  
44. Sugiura H, Liu X, Togo S, Kobayashi T, Shen L, Kawasaki S, Kamio K, Wang XQ, Mao LJ, Rennard SI. 
Prostaglandin E(2) protects human lung fibroblasts from cigarette smoke extract-induced apoptosis 
via EP(2) receptor activation. J Cell Physiol 2007;210:99–110.  
45. Kay LJ, Yeo WW, Peachell PT. Prostaglandin E2 activates EP2 receptors to inhibit human lung 
mast cell degranulation. Br J Pharmacol 2006;147:707–713.   
46. Weller CL, Collington SJ, Hartnell A, Conroy DM, Kaise T, Barker JE, Wilson MS, Taylor GW, Jose 
PJ, Williams TJ. Chemotactic action of prostaglandin E2 on mouse mast cells acting via the PGE2 
receptor 3. Proc Natl Acad Sci USA 2007;104:11712–11717.   
